VTRS Q3 2023 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B-3.3% YoY

Gross Profit

$1.7B42.9% margin

Operating Income

$452M11.5% margin

Net Income

$332M8.4% margin

EPS (Diluted)

$0.27

QoQ Revenue Growth

+0.6%

Cash Flow

Operating Cash Flow

$835M

Free Cash Flow

$732M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$48.7B

Total Liabilities

$27.9B

Stockholders' Equity

$20.9B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$4.1B	-3.3%
Gross Profit	$1.7B	$1.7B	-3.3%
Operating Income	$452M	$560M	-19.4%
Net Income	$332M	$354M	-6.4%

Revenue Segments

Brands

$2.5B64%

Generics

$1.2B31%

Complex GX and Biosimilars

$174M4%

Geographic Segments

Developed Markets Segment

$2.4B61%

Emerging Markets Segment

$643M16%

Greater China Segment

$548M14%

Japan, Australia and New Zealand Segment

$335M9%